Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0K5UF
|
||||
| Former ID |
DIB019609
|
||||
| Drug Name |
compound 8e
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Discovery agent | Investigative | [1] | ||
| Structure |
|
Download2D MOL |
|||
| Formula |
C22H23FN6O3S
|
||||
| InChI |
InChI=1S/C22H23FN6O3S/c1-12-19(33-21(28-12)22(3,31)11-30)14-8-18(20(24)25-10-14)32-13(2)16-9-15(23)4-5-17(16)29-26-6-7-27-29/h4-10,13,30-31H,11H2,1-3H3,(H2,24,25)/t13-,22-/m1/s1
|
||||
| InChIKey |
DIXMBHMNEHPFCX-MCMMXHMISA-N
|
||||
| PubChem Compound ID | |||||
| PubChem Substance ID | |||||
| Target and Pathway | |||||
| Target(s) | fer (fps/fes related) tyrosine kinase | Target Info | Inhibitor | [1] | |
| ALK tyrosine kinase receptor | Target Info | Inhibitor | [1] | ||
| leukocyte receptor tyrosine kinase | Target Info | Inhibitor | [1] | ||
| BDNF/NT-3 growth factors receptor | Target Info | Inhibitor | [1] | ||
| FES proto-oncogene, tyrosine kinase | Target Info | Inhibitor | [1] | ||
| ROS1 | Target Info | Inhibitor | [1] | ||
| KEGG Pathway | Non-small cell lung cancerhsa04010:MAPK signaling pathway | ||||
| Neurotrophin signaling pathway | |||||
| Alcoholism | |||||
| Pathway Interaction Database | SHP2 signaling | ||||
| Posttranslational regulation of adherens junction stability and dissassembly | |||||
| Neurotrophic factor-mediated Trk receptor signaling | |||||
| Reactome | NGF-independant TRKA activation | ||||
| WikiPathways | Differentiation PathwayWP706:SIDS Susceptibility Pathways | ||||
| BDNF signaling pathwayWP2431:Spinal Cord Injury | |||||
| References | |||||
| REF 1 | Design of potent and selective inhibitors to overcome clinical anaplastic lymphoma kinase mutations resistant to crizotinib. J Med Chem.> 2014 Feb 27;57(4):1170-87. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.